Company intelligence / Profile preview

Wintermute Biomedical

Corvallis / Missoula, Montana, United Stateswintermutebiomedical.com ↗

Ownership: Private
Employees: ~7
Development stage: Other

Overview

Lead product Solexan has completed a Phase Ib randomized controlled trial as a topical antiviral for shingles. The technology demonstrates broad-spectrum antimicrobial activity with low toxicity and no observed resistance in standardized testing. Additional programs are in preclinical or early clinical stages targeting MRSA and Buruli ulcers.

Therapeutic areas: Infectious Diseases
Modalities: Small moleculePolymer-drug conjugate therapy (antimicrobial micelles based on fatty acids and amino acids)
Industry: Biotech

Drug pipeline

3 assets

GS-2

Preclinical

2 more assets in the full pipeline.

Request access →

Partnerships

CoActive Health Solutions provides development support/advisory services; seeking further partners/funders for pivotal trials.

Beyond the preview

Go deeper on Wintermute Biomedical.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Wintermute Biomedical.

Explore the full profile